Letter (message)

POSaBIT to Acquire MJ Platform, Leaf Data Systems and Ample Organics for US$4 Million Adding 350+ Merchants and More than US$2 Billion in GMV

Retrieved on: 
Friday, January 27, 2023
Professional Services, Payments, Cannabis, Technology, Natural Resources, Finance, Fintech, Indian stock exchange, PBIT, EBITDA, Acquiring bank, Letter (message), Perga, OTC, Data, CSE, Warrant, PIN, Calendar, GMV, Unit, Commitment, POS, Letter, Acquisition, Security (finance), Bank

Importantly, this transaction launches us to the top five POS providers in terms of market share and GMV.

Key Points: 
  • Importantly, this transaction launches us to the top five POS providers in terms of market share and GMV.
  • It adds valuable assets that align directly with our stated goals of adding new merchants, increasing digital payment penetration and introducing new offerings to better serve our merchants.
  • We are adding new team members and our pipeline of both organic and strategic opportunities is expanding.
  • We welcome the talented professionals that will help convert this pipeline of opportunities and build upon our category leadership.

EQS-News: Adler Group S.A.: Adler reaches agreement with bondholder group on amendment of note terms and provision of secured debt financing

Retrieved on: 
Sunday, November 27, 2022
Adler, PJT Partners, Senior management, 9/11 Family Steering Committee, Attention, White, Houlihan Lokey, Consus, Committee, Maintenance, Contingent value rights, Letter, New Money, White & Case, Letter (message), Commitment, News, Security (finance), Interior design, Management, Lease, Credit, Note

The 2023 convertible notes of Adler Group are not subject to the agreement.

Key Points: 
  • The 2023 convertible notes of Adler Group are not subject to the agreement.
  • Adler Group is appreciative of the efforts of the Steering Committee in enabling this important milestone to be achieved.
  • Adler Group has been advised by PJT Partners as financial and White & Case LLP as legal advisor.
  • Adler Group will shortly launch a consent solicitation process to effect certain amendments to the terms and conditions of the Notes.

Clene Reports Third Quarter 2022 Financial Results and Recent Operating Highlights

Retrieved on: 
Monday, November 7, 2022
SALT, Committee, EMA, Gold, European Medicines Agency, Population, Accounting, Securities Exchange Act of 1934, Ventilation, Marketing, Maryland Department of Commerce, Income, Research, ALS, Annual report, Clinical trial, LS, R, Program, Company, Mortality, EAP, GLOBE, Amyotrophic lateral sclerosis, CEO, Securities Act of 1933, Initial, Community, Housing, Patient, MS, Sale, Letter, COVID-19, Review, Mitt, Remyelination, Neuroprotection, CNM, Eye, Survival, Investment, Community development, Letter (message), Death, Safety, AMG, COMP, Nasdaq, Neurodegeneration, EAPS, Healey, Risk, Pharmaceutical industry, Medical imaging, Cryptocurrency, Hydraulic machinery, Facebook

SALT LAKE CITY, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, Clene) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today reported its third quarter 2022 financial results and recent operating highlights.

Key Points: 
  • SALT LAKE CITY, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, Clene) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today reported its third quarter 2022 financial results and recent operating highlights.
  • To our knowledge, this is the only study to show a survival benefit at 6-months in ALS, said Rob Etherington, President and CEO of Clene.
  • Research and development expenses were $6.4 million for the quarter ended September 30, 2022, compared to $6.1 million for the same period in 2021.
  • General and administrative expenses were $3.6 million for the quarter ended September 30, 2022, compared to $4.4 million for the same period in 2021.

Gamida Cell Announces Entry into Commitment Letter with Highbridge for $25 Million Financing

Retrieved on: 
Wednesday, September 28, 2022
Oncology, Health, Stem Cells, General Health, Pharmaceutical, Biotechnology, Hospital, Risk, Therapy, Safety, Infection, Trial of the century, COVID-19, Transplant, Twitter, Lymphatic system, FDA, ADCC, LLC, Hematology, Phenotype, LinkedIn, Population, Highbridge, Breakthrough therapy, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, NK, Patient, Clinical trial, Facebook, Immunotherapy, Letter (message), Letter, Technology, Instagram, Cell, Bone marrow, B cell, Security (finance), BLA, Graft-versus-host disease, SEC, Mortality, NAM, Highbridge Capital Management, Bank, Pharmaceutical industry, Vaccine, EU

The Commitment Letter does not represent a definitive credit facility and is subject to certain conditions, including the consummation of a Gamida Cell equity offering resulting in gross proceeds of not less than $20 million.

Key Points: 
  • The Commitment Letter does not represent a definitive credit facility and is subject to certain conditions, including the consummation of a Gamida Cell equity offering resulting in gross proceeds of not less than $20 million.
  • Omidubicel is an advanced cell therapy candidate developed as a potential life-saving allogeneic hematopoietic stem cell (bone marrow) transplant for patients with blood cancers.
  • For additional information, please visit www.gamida-cell.com or follow Gamida Cell on LinkedIn , Twitter , Facebook or Instagram at @GamidaCellTx.
  • Although Gamida Cells forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Gamida Cell.

RISING ABOVE BARRIERS: TECH STARTUP RISEKIT HELPS UNDERSERVED JOB SEEKERS FIND MEANINGFUL EMPLOYMENT

Retrieved on: 
Monday, September 19, 2022
Software, Ethnic groups in Chicago, Chicago Urban League, Chicago Public Schools, Employment, McDonald's, Macdonald, Religion, Organization, LinkedIn, Life, Monster, Chicago Department of Public Health, History, City, Interview, Cigna, Education, Letter (message), Housing, Management, Tutoring, Easterseals (U.S.), Amazon

Its unique software connects job seekers with employers who work with them to ensure their success.

Key Points: 
  • Its unique software connects job seekers with employers who work with them to ensure their success.
  • Once they sign up, applicants will receive resume help, mock interview support, and job readiness training.
  • RiseKit has partnered with the City of Chicago Department of Family Support Services in over 50 workforce programs.
  • Jemome K: Got help from the non-profit group "All Chicago" to receive housing and ended up getting a job.

DGAP-News: Generation Income Properties Announces Amended Commitment from American Momentum Bank to Change Rate Index

Retrieved on: 
Wednesday, September 14, 2022
Momentum, COVID-19, American Momentum Bank, Risk, CME, Association, Nature, Company, AMB, SOFR, Private Securities Litigation Reform Act, Letter (message), Investment, Asset-backed security, CEO, Annual report, NASDAQ, SEC, GIPR, Income, Bank

Generation Income Properties, Inc. (NASDAQ: GIPR) (GIPR or the Company) announced the amendment and restatement of its previously disclosed commitment letters with American Momentum Bank (AMB).

Key Points: 
  • Generation Income Properties, Inc. (NASDAQ: GIPR) (GIPR or the Company) announced the amendment and restatement of its previously disclosed commitment letters with American Momentum Bank (AMB).
  • Additional information about Generation Income Properties, Inc. can be found at the Companys corporate website: www.gipreit.com .
  • American Momentum Bank, a Texas-chartered banking association with total assets of $2.8 billion as of June 30, 2022, provides comprehensive products and services for businesses and individuals.
  • American Momentum Bank has 18 full-service banking centers in Texas and nine full-service banking centers in Florida.

College of Charleston Named Academic Partner for Charleston Literary Festival

Retrieved on: 
Friday, July 29, 2022
Association, Horse, Biography, Charleston Library Society, Democracy, College, GLOBE, South Carolina Lowcountry, The Plot, New Yorker, Letter (message), Human, Student, Opening Night, History, The New York Times, Chicago Tribune, House, Religion, The Diana Chronicles, Chicago, The Washington Post, Plot, Alumni association, Grief, Time, Science, Dock Street Theatre, Circular Congregational Church, Faculty, Survival, Guilt, Love, Pulitzer Prize, The New Yorker, Animal, Book, Vanity Fair, Entertainment, Management, Tatler

Charleston SC, July 29, 2022 (GLOBE NEWSWIRE) -- For the second consecutive year, the College of Charleston has been chosen as the exclusive academic partner for the Charleston Literary Festival.

Key Points: 
  • Charleston SC, July 29, 2022 (GLOBE NEWSWIRE) -- For the second consecutive year, the College of Charleston has been chosen as the exclusive academic partner for the Charleston Literary Festival.
  • The College of Charleston is honored to partner with this extraordinary festival again, says Suzanne Austin, executive vice president for academic affairs and provost.
  • As the academic partner, the College of Charleston and its Alumni Association will provide financial, promotional and logistical support to the festival.
  • The Charleston Literary Festival is an independent 501(c)3 nonprofit organization with a distinct transatlantic focus.

Blue Earth Diagnostics Announces Additional Results from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Biochemical Recurrence of Prostate Cancer

Retrieved on: 
Friday, May 13, 2022
Science, Radiology, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Google Images, Disease, Magnetic resonance imaging, Food, Membrane, MRI, Cardiac catheterization, Salvage therapy, Magnetic resonance, Plenary session, Cancer, Institute of technology, Physician, 3D ultrasound, Standard, Journal, Letter (message), Therapy, Man, Acquisition, Multimedia, Technical University of Munich, Health, Solution, PET, Radiation, FDA, Recurrence, Interventional radiology, The Journal of Urology, EAP, CEUS, ASCO, Prostatectomy, Isotope, Radiopharmaceutical, PSMA, CDR, Molecular imaging, Nuclear medicine, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, Prostate cancer, Safety, Precision medicine, Medical imaging, MD

Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced results of additional endpoints from its Phase 3 SPOTLIGHT trial of 18F-rhPSMA-7.3 in recurrent prostate cancer.

Key Points: 
  • Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced results of additional endpoints from its Phase 3 SPOTLIGHT trial of 18F-rhPSMA-7.3 in recurrent prostate cancer.
  • Conventional imaging techniques have many limitations in prostate cancer identification and localization, and greater imaging accuracy is needed throughout the care continuum to optimize therapeutic decision-making.
  • Blue Earth Diagnostics has completed two Phase 3 clinical studies evaluating the safety and diagnostic performance of 18F-rhPSMA-7.3 PET imaging in prostate cancer: (SPOTLIGHT, NCT04186845 ), in men with recurrent disease and (LIGHTHOUSE, NCT04186819 ), in men with newly diagnosed prostate cancer.
  • Blue Earth Diagnostics expanding oncology portfolio encompasses a variety of disease states, including prostate cancer and neuro-oncology.

The Cheesecake Factory Incorporated Commits to Reduce Carbon Emissions in Alignment With the Paris Agreement

Retrieved on: 
Friday, April 22, 2022
Retail, Restaurant, Bar, Environment, Food, Beverage, Corporate social responsibility, Climate, Unemployment, Phrase, Carbon, Climate change, U.S. Securities and Exchange Commission, COVID-19, Security (finance), Risk, Social responsibility, NASDAQ, Annual report, Magazine, Collection, Restaurant, Compliance, Private Securities Litigation Reform Act, Revenue stream, Organization, CSR, America's Climate Security Act of 2007, Goal, Letter (message), Securities Exchange Act of 1934, Internal Revenue Service, Science, Review, The Cheesecake Factory, Environmental Health (journal), Sustainability, SEC, Paris, Letter, Forward-looking statement, Risk management, Policy, As You Sow, Public health, Sumathi Best Television Current Reporting Award, FORTUNE, Industry, Pandemic, Paris Agreement, Health, Cheesecake, Securities Act of 1933, Government, Renewable energy, Waste

The Cheesecake Factory Incorporated (NASDAQ: CAKE) today announced that it is committed to reducing its carbon emissions in alignment with the Paris Agreement, an international agreement adopted to address climate change and its negative impacts by limiting global warming to 1.5-degrees Celsius.

Key Points: 
  • The Cheesecake Factory Incorporated (NASDAQ: CAKE) today announced that it is committed to reducing its carbon emissions in alignment with the Paris Agreement, an international agreement adopted to address climate change and its negative impacts by limiting global warming to 1.5-degrees Celsius.
  • We are very pleased to be committing to reduce our carbon emissions as part of that strategy.
  • Making this commitment is a wonderful progression that builds upon our award-winning sustainable sourcing and food recovery programs, said Megan Bloomer, Vice President of Sustainability for The Cheesecake Factory Incorporated.
  • And, we are encouraged to see companies like The Cheesecake Factory set science-based goals to align with a 1.5-degree carbon reduction scenario.

Duet Protocol Announces New Investors Including GSR, DHVC and Raises the Total Funding to 5 Million USD

Retrieved on: 
Wednesday, March 9, 2022
Consensus, NASDAQ, Duet, Letter (message), GSR, Investment, Decentralized finance, A&T, Cryptocurrency

Singapore, Singapore--(Newsfile Corp. - March 9, 2022) - Duet Protocol, the world's first multi-chain synthetic asset protocol with a hybrid mechanism, announced on March 9th, 2022 its financing progress and new partners.

Key Points: 
  • Singapore, Singapore--(Newsfile Corp. - March 9, 2022) - Duet Protocol, the world's first multi-chain synthetic asset protocol with a hybrid mechanism, announced on March 9th, 2022 its financing progress and new partners.
  • Previously, Duet had raised US$3 million from world-renowned investors including OmniLAB, DraperDragon, Everest Ventures Group, One Block Capital, Moonwhale Ventures, etc.
  • In this round of investment, Duet has raised an additional 2 million USD from the investors to take the raise to a total of 5 million USD.
  • In the short run, the receipt token holders can enhance their returns by utilizing stablecoins minted with Duet protocol.